Table 2 (abstract P105). Proportion of Participants in the long-term safety trial with an Initial Response of ≥50%, ≥75% or 100% Reduction in MMD with Sustained Response through to Q4
From: 16th European Headache Congress 2022 meeting abstracts
From: 16th European Headache Congress 2022 meeting abstracts